SCHEMBL14710342

SCHEMBL14710342

Clc1nsnc1-c1ccc(Br)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
NPSR1 Q6W5P4 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
RXFP1 Q9HBX9 1/20 0.38
MAPT P10636 6/20 0.37
ALDH1A1 P00352 4/20 0.37
KDM4E B2RXH2 2/20 0.37
POLB P06746 1/20 0.37
HSP90AA1 P07900 1/20 0.37
MPI P34949 1/20 0.37
HTT P42858 1/20 0.37
CACNA1B Q00975 1/20 0.37
APBA1 Q02410 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
LMNA P02545 2/20 0.37
MAPK1 P28482 2/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2C9 P11712 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8935466 0.83 KDM4E (0.41) NPC1RAB9AKMT2AMAPTALDH1A1
SCHEMBL10986432 0.79 ESR1 (0.40) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL544426 0.78 KDM4E (0.47) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL9393916 0.77 MAPT (0.42) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL30704358 0.75 ALOX15 (0.37) NPC1RAB9ANPSR1MEN1KMT2A
SCHEMBL8935540 0.75 DGAT1 (0.41) NPC1RAB9ANPSR1MEN1KMT2A
SCHEMBL10984490 0.75 ALDH1A1 (0.46) NPC1RAB9ANPSR1KMT2AMAPT
SCHEMBL31337354 0.73 NPC1 (0.46) NPC1RAB9ANPSR1MEN1KMT2A
SCHEMBL18748042 0.72 MAPT (0.39) NPC1RAB9ANPSR1MEN1KMT2A
SCHEMBL10987713 0.71 CHRM2 (0.39) RAB9ANPSR1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975235-B2 Lysophosphatidic acid receptor antagonists INTERMUNE, INC. (US) 2015-03-10 US disclosed
US-8975235-B2 Lysophosphatidic acid receptor antagonists INTERMUNE, INC. (US) 2015-03-10 US disclosed
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-03-21 US disclosed
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-03-21 US disclosed
WO-2013025733-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS LPAR1, LPAR2, LPAR5 NPC1 383/4885RAB9A 2005/4885NPSR1 259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.